tradingkey.logo
tradingkey.logo
Search

Medpace Holdings Inc

MEDP
Add to Watchlist
577.110USD
-1.190-0.21%
Close 07-31 16:00ETQuotes delayed by 15 min
16.44BMarket Cap
35.57P/E TTM

More Details of Medpace Holdings Inc Company

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.

Medpace Holdings Inc Info

Ticker SymbolMEDP
Company nameMedpace Holdings Inc
IPO dateAug 11, 2016
CEOTroendle (August J)
Number of employees5900
Security typeOrdinary Share
Fiscal year-endAug 11
Address5375 Medpace Way
CityCINCINNATI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code45227-1543
Phone15135799911
Websitehttps://investor.medpace.com/
Ticker SymbolMEDP
IPO dateAug 11, 2016
CEOTroendle (August J)

Company Executives of Medpace Holdings Inc

Name
Name/Position
Position
Shareholding
Change
Dr. August J. Troendle, M.D.
Dr. August J. Troendle, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
646.18K
--
Mr. Brian T. Carley
Mr. Brian T. Carley
Independent Director
Independent Director
32.86K
+0.11%
Mr. Stephen P. Ewald, J.D.
Mr. Stephen P. Ewald, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
20.34K
--
Mr. Jesse J. Geiger, CPA
Mr. Jesse J. Geiger, CPA
President
President
15.00K
--
Mr. Robert O. Kraft
Mr. Robert O. Kraft
Independent Director
Independent Director
988.00
+3.34%
Ms. Susan E. Burwig
Ms. Susan E. Burwig
Executive Vice President - Operations
Executive Vice President - Operations
--
--
Mr. Fred B. Davenport, Jr.
Mr. Fred B. Davenport, Jr.
Lead Independent Director
Lead Independent Director
--
--
Mr. Cornelius P. Mccarthy, III
Mr. Cornelius P. Mccarthy, III
Independent Director
Independent Director
--
--
Mr. Kevin M. Brady
Mr. Kevin M. Brady
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Femida H. Gwadry-Sridhar
Dr. Femida H. Gwadry-Sridhar
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. August J. Troendle, M.D.
Dr. August J. Troendle, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
646.18K
--
Mr. Brian T. Carley
Mr. Brian T. Carley
Independent Director
Independent Director
32.86K
+0.11%
Mr. Stephen P. Ewald, J.D.
Mr. Stephen P. Ewald, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
20.34K
--
Mr. Jesse J. Geiger, CPA
Mr. Jesse J. Geiger, CPA
President
President
15.00K
--
Mr. Robert O. Kraft
Mr. Robert O. Kraft
Independent Director
Independent Director
988.00
+3.34%
Ms. Susan E. Burwig
Ms. Susan E. Burwig
Executive Vice President - Operations
Executive Vice President - Operations
--
--

FAQs

Who are the top five shareholders of Medpace Holdings Inc?

The top five shareholders of Medpace Holdings Inc are: Dr. August J. Troendle, M.D.

How many institutions hold shares of Medpace Holdings Inc (MEDP)?

As of 2026Q1, 1402 institutions hold shares of Medpace Holdings Inc, with a combined market value of approximately 24.53M, accounting for 85.88% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2462776.00.

What is the biggest source of revenue for Medpace Holdings Inc?

In 2026Q1, the Oncology business generated the highest revenue for Medpace Holdings Inc, amounting to 747.59M and accounting for 29.55% of total revenue.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.